The product is designed to immediately improve the appearance of the eyes and continues reducing the visible signs of aging and fatigue over time-including dark circles, fine lines and crepiness of upper eyelids. For its most comprehensive regimen,
'We know from the Allergan 360-degree Aesthetics Report that globally, women state the eye area as a top concern. By harnessing the key ingredients from two of our most popular products, Lytera 2.0 Pigment Correcting Serum and HA5 Rejuvenating Hydrator, and pairing them with new technology, we created a new and unique product that addresses this top concern,' says
The cream was clinically reported to show visible results within 15 minutes of application. Additionally, 95% of patients reported satisfaction at eight weeks and continued satisfaction at twelve weeks, reporting that their eyes looked brighter, refreshed and less tired (n=41).
'Photodamage, oxidative stress, and lifestyle factors all affect the delicate skin around the eyes and can cause this area to look tired and dull. Aging skin only exacerbates the problem and these concerns become more prominent over time,' says Dr.
For nearly two decades,
About
With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers, and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing and other risks and uncertainties detailed in Allergan's periodic public filings with the
Contact:
Tel: (862) 261-7488
(C) 2020 Electronic News Publishing, source